Inhibition of activation-induced death of dendritic cells and enhancement of vaccine efficacy via blockade of MINOR

Blood

Volumn 113, Issue 13, 2009, Pages 2906-2913

  Wang, Tianhong ^a   Jiang, Qiong ^b   Chan, Camie ^c,d   Gorski, Kevin S ^e   McCadden, Erin ^a   Kardian, David ^a   Pardoll, Drew ^a   Whartenby, Katharine A ^a,f  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b SABiosciences   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SHRINERS HOSPITALS FOR CHILDREN NORTHERN CALIFORNIA   (United States)

^e AMGEN INC   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; INTERLEUKIN 12; LENTIVIRUS VECTOR; NUCLEAR RECEPTOR NUR77; NUCLEAR RECEPTOR RELATED FACTOR 1; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL DEATH; CELL MATURATION; CELL SURVIVAL; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; GENE INDUCTION; GENE OVEREXPRESSION; GENE SILENCING; MACROPHAGE; MITOGEN INDUCIBLE NUCLEAR ORPHAN RECEPTOR GENE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; REGULATOR GENE; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; UPREGULATION;

EID: 63849118531     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-08-176354     Document Type: Article

References (27)

1. Hermans IF, Ritchie DS, Yang J, Roberts JM, Ronchese F. CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J Immunol. 2000;164:3095- 3101.
2. Kamath AT, Henri S, Battye F, Tough DF, Shortman K. Developmental kinetics and life span of dendritic cells in mouse lymphoid organs. Blood. 2002;100:1734-1741.
3. Leverkus M, Walczak H, McLellan A, et al. Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apo-ptosis. Blood. 2000;96:2628-2631.
4. Willems F, Amraoui Z, Vanderheyde N, et al. Expression of c-FLIP(L) and resistance to CD95- mediated apoptosis of monocyte-derived dendritic cells: inhibition by bisindolylmaleimide. Blood. 2000;95:3478-3482.
5. McLellan A, Heldmann M, Terbeck G, et al. MHC class II and CD40 play opposing roles in dendritic cell survival. Eur J Immunol. 2000;30:2612-2619.
6. Wong BR, Josien R, Lee SY, et al. TRANCE (tumor necrosis factor [TNF-]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med. 1997;186:2075-2080.
7. Eggert AA, Schreurs MW, Boerman OC, et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res. 1999;59:3340-3345.
8. Cayeux S, Richter G, Becker C, Pezzutto A, Dorken B, Blankenstein T. Direct and indirect T cell priming by dendritic cell vaccines. Eur J Immunol. 1999;29:225-234.
9. Esche C, Gambotto A, Satoh Y, et al. CD154 inhibits tumor-induced apoptosis in dendritic cells and tumor growth. Eur J Immunol. 1999;29:2148-2155.
10. Cheng LE, Chan FK, Cado D, Winoto A. Functional redundancy of the Nur77 and Nor-1 orphan steroid receptors in T-cell apoptosis. EMBO J. 1997;16:1865-1875.
11. Liu ZG, Smith SW, McLaughlin KA, Schwartz LM, Osborne BA. Apoptotic signals delivered through the T-cell receptor of a T-cell hybrid require the immediate-early gene nur77. Nature. 1994;367:281-284.
12. Hazel TG, Misra R, Davis IJ, Greenberg ME, Lau LF. Nur77 is differentially modified in PC12 cells upon membrane depolarization and growth factor treatment. Mol Cell Biol. 1991;11:3239-3246.
13. Philips A, Lesage S, Gingras R, et al. Novel dimeric Nur77 signaling mechanism in endocrine and lymphoid cells. Mol Cell Biol. 1997;17:5946- 5951.
14. Winoto A, Littman DR. Nuclear hormone receptors in T lymphocytes. Cell. 2002;109[suppl]:S57-S66.
15. Kim SO, Ono K, Tobias PS, Han J. Orphan nuclear receptor Nur77 is involved in caspase- independent macrophage cell death. J Exp Med. 2003;197:1441-1452.
16. Gorski KS, ShinT, Crafton E, et al. A set of genes selectively expressed in murine dendritic cells: utility of related cis-acting sequences for lentiviral gene transfer. Mol Immunol. 2003;40:35-47.
17. Henri S, Vremec D, Kamath A, et al. The dendritic cell populations of mouse lymph nodes. J Immunol. 2001;167:741-748.
18. Vremec D, Pooley J, Hochrein H, Wu L, Shortman K. CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J Immunol. 2000;164:2978-2986.
19. Cui Y, Kelleher E, Straley E, et al. Immunotherapy of established tumors using bone marrow trans-plantation with antigen gene-modified hematopoietic stem cells. Nat Med. 2003;9:952-958.
20. GenBank. http://www.ncbi.nlm.nih.gov/sites/ entrez?cmd=search&term= 7657397&db=protein. Accessed December 24, 2008.
21. National Center for Biotechnology Information. http://blast.ncbi.nlm.nih. gov/Blast.cgi. Accessed December 24, 2008.
22. Paczesny S, Ueno H, Fay J, Banchereau J, Palucka AK. Dendritic cells as vectors for immu- notherapy of cancer. Semin Cancer Biol. 2003;13:439-447.
23. Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev. 2007;220:129-150.
24. MartIn-Fontecha A, Sebastiani S, Hopken UE, et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med. 2003;198:615-621.
25. Kim TW, Hung CF, Boyd D, et al. Enhancing DNAvaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol. 2003;171:2970-2976.
26. Kim TW, Hung CF, Ling M, et al. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest. 2003; 112:109-117.
27. Kim TW, Lee JH, He L, et al. Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res. 2005;65:309-316.